Financial Data and Key Metrics Changes - The company reported total revenue growth of 9% for 2023, including 8% organic growth, aligning with its high single-digit strategic goal [25] - Adjusted gross margin for Q4 was 58.6%, up 150 basis points year-over-year, driven by higher sales leverage, favorable product mix, and cost discipline [18] - Adjusted EBITDA margin for Q4 was 18%, down 30 basis points compared to 2022, attributed to one-time cost benefits in 2022 and dilution from recent acquisitions [38] Business Line Data and Key Metrics Changes - The Recon segment achieved full-year organic growth of 14%, with Q4 growth of 11% [6][8] - The P&R segment experienced nearly 5% organic growth for the full year, with Q4 growth of 6% [26][8] - Gross margins in the Recon segment expanded by 240 basis points due to pricing and productivity improvements [11] Market Data and Key Metrics Changes - The U.S. market for Recon saw double-digit growth, with 11% organic growth in Hip & Knee and Extremities [29] - Internationally, the Recon segment also grew 11% organically, indicating resilience in the market [29] - The elective surgery markets served by the company are expected to remain healthy, with potential for above-normal demand in 2024 [8] Company Strategy and Development Direction - The company aims to integrate Lima and execute major new product launches in 2024, expecting transformative growth [12] - The focus remains on expanding the Recon business and enhancing innovation capabilities through strategic acquisitions [27] - The company is committed to leveraging its EGX capabilities to drive productivity and margin improvements across its business segments [39] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to drive compounding growth and margin expansion despite external headwinds [12] - There is an expectation of pent-up demand for elective surgeries, which could lead to above-market growth in the Recon segment [76] - The company anticipates a strong operating performance in 2024, projecting revenues between $2.05 billion and $2.15 billion [63] Other Important Information - The company has a robust innovation pipeline, including new products like the EMPOWR Revision Knee and the ROAM OA brace [10][34] - The Lima acquisition is expected to contribute significantly to revenue and operational synergies, with a target of $70 million to $75 million in EBITDA contribution [44][88] Q&A Session Summary Question: How did the Q4 Recon growth compare to market expectations? - Management indicated that the 11% growth in Recon was in line with expectations, emphasizing the importance of looking at multi-year trends for a clearer picture [68] Question: What is the outlook for margin expansion with the integration of Lima? - Management expressed confidence in achieving at least 50 basis points of core margin improvement while integrating Lima, with expectations for $40 million in cost synergies by year three [59][84] Question: What are the expectations for the new product cycle and market growth? - Management highlighted a healthy pipeline of new products and anticipated continued growth in both Recon and P&R segments, with a focus on filling white spaces in the market [71][119] Question: How is the competitive landscape affecting guidance? - Management stated that guidance accounts for the full competitive environment, emphasizing the company's leadership in innovation and technology [90] Question: What are the anticipated impacts of GLP-1s on patient volumes? - Management noted that while there is potential for increased patient volumes due to GLP-1s, it is not expected to have a meaningful impact in the short term [79]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________ Form 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______to_______ Commission file number 001-34045 _________________________ ENOVIS CORPORATION (Exact name of registrant as specified in its charter) S ...

Enovis' fourth-quarter net sales of $455 million grew 11% from the same quarter in 2022, including 8% organic growth. Fourth quarter results reflect continued execution in P&R, above-market growth in Recon, and the impact of recent acquisitions. Compared to the same quarter in 2022, net sales in Recon grew 18%, with 11% organic sales growth, and P&R grew 8%, with 6% organic sales growth. Enovis also reported a fourth-quarter net income from continuing operations of $3 million and adjusted EBITDA of $82 mill ...

WILMINGTON, DE, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven, medical technology company, will showcase its latest technologies across the orthopedic care continuum at the American Academy of Orthopedic Surgeons Annual Meeting 2024. In addition, the Company will present itself as a newly integrated company following the acquisition of orthopedic leader LimaCorporate S.p.A ("Lima"). "Enovis has a lot to be excited about in 2024. In our Surgical business, the additio ...

WILMINGTON, DE, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Today, Enovis™ Corporation (NYSE:ENOV), an innovation-driven medical technology company, announced it will showcase the latest technologies from its Global Foot and Ankle business at the American College of Foot & Ankle (ACFAS) annual meeting in Tampa, Fla., from February 1-4, 2024. The company will feature products from its recent acquisitions of Novastep® and the external fixation assets of D.N.E., LLC, along with the internally developed Evolve34™ Lapidus ...

威爾明頓，特拉華州, Jan. 04, 2024 (GLOBE NEWSWIRE) -- 創新驅動的醫療技術成長型公司 Enovis™ Corporation （NYSE: ENOV，以下簡稱「Enovis」或「公司」）今日宣布已完成對 LimaCorporate S.p.A （以下簡稱「Lima」）的收購。Lima 是一家私人控股的全球骨科領先企業，專注於透過創新的植入解決方案組合恢復運動功能。 Lima 憑藉成熟的手術解決方案和技術的互補性產品組合，鞏固了 Enovis 在全球骨科重建市場的地位，這將加速公司的全球增長和利潤擴張。此外，Lima 的產品組合包括 3D 打印 Trabecular Titanium 植入物和全面的肩部修復產品，這將進一步加強該公司在快速成長的四肢市場中的地位。 「我們很高興歡迎 Lima 的優秀團隊加入 Enovis。此次合併使 Enovis 的重建分部收入達到 10 億美元，並成為全球骨科重建市場快速成長的創新者。這是我們如何利用策略性收購來加速成長、為公司增添優秀技術和人才、以及為股東帶來複合價值的又一範例。」Enovis 董事長兼行政總裁 Matt Trerotol ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34045 Enovis Corporation (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 (State or other jurisdiction of incorporation or organization) Delaware 54-1887631 (I.R.S. Employer Identification No.) 2711 Centerville Road, Suite 400 Wilmington, Delaware 19808 (Address of principal executive offices) (Zip Code) OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SEC ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________ Form 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______to_______ Commission file number 001-34045 _________________________ ENOVIS CORPORATION (Exact name of registrant as specified in its charter) S ...

Financial Data and Key Metrics Changes - The company reported a 15% growth in organic revenue and a 32% increase in adjusted EPS for Q3 2021, despite a challenging environment [7][46] - Total company EBITDA margins grew by 20 basis points, with a 90 basis point improvement before the effect from acquisitions [45] Business Line Data and Key Metrics Changes - ESAB exceeded expectations with a 24% increase in total sales, driven by high single-digit volume growth and a 15-point price increase [36] - MedTech sales increased by 40%, with organic sales per day growth of 1%, impacted by a 2-point headwind from one-time sales in Q3 last year [11][50] Market Data and Key Metrics Changes - In the Americas, ESAB volumes rose by 11%, while EMEA and APAC increased by 6% compared to the same period last year [37] - The MedTech business experienced a 14% growth over Q3 2020, with organic sales per day growth of 3% excluding PPE [50] Company Strategy and Development Direction - The company is on track for a tax-free spin-off of its ESAB business, targeting separation in Q1 2022, with substantial progress in creating independent boards and filling key leadership positions [10][30] - The new corporate name, Enovis, symbolizes a strategic pivot to a specialty MedTech company focused on innovative solutions [29][30] Management's Comments on Operating Environment and Future Outlook - Management noted that the recovery of elective surgeries is expected to improve gradually, with a potential for market growth in the coming years as backlogged procedures are addressed [72][74] - The company anticipates continued operational improvements and margin expansion, despite challenges from supply chain inflation and inefficiencies [16][100] Other Important Information - The company is implementing price increases to offset inflation and expects sequential margin improvement in Q4 [17][56] - The integration of recent acquisitions is progressing well, with expectations for significant revenue growth and cost synergies [25][28] Q&A Session Summary Question: What steps are left to complete the split? - Management indicated that they are well into the process, with key leadership positions filled and capital structure aligned, expecting no significant challenges [60] Question: How is the MedTech recovery expected to progress? - Management noted a 5% pressure on elective surgeries due to COVID, but they anticipate gradual improvement and a return to normal levels in 2022 [72][74] Question: What is the pricing strategy in MedTech? - Management explained that pricing can be passed through in some areas, while others depend on reimbursement rates, which may take time to adjust [63][117] Question: How are supply chain issues being managed? - Management highlighted the use of CBS tools to improve customer service and manage supply chain challenges effectively [78] Question: What are the growth expectations for the MedTech business? - Management expects the recon business to grow in healthy double digits, while the P&R business is positioned to grow at or above market rates [111][112]